Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $35.75 USD
Change Today +0.29 / 0.82%
Volume 358.6K
As of 11:40 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

320 Wakara Way

Salt Lake City, UT 84108

United States

Phone: 801-584-3600

Fax: 801-584-3640

ates, including neuroscience disorders, infectious diseases, and inflammatory diseases. Myriad RBM has strategic collaborations with approximately 20 major pharmaceutical and biotechnology companies, which coupled with its position in PARP inhibitor and PI3K inhibitor pharmaceutical and clinical services, as well as creates a major franchise in pharmaceutical and clinical services. In addition, its acquisition of Myriad RBM has provided the company with access to samples from additional patient cohorts for new molecular diagnostic test development and clinical validation activities. The company, through Myriad RBM, provides biomarker discovery and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries utilizing its multiplexed immunoassay technology. The company’s pharmaceutical and clinical services consist of the following: MAP: The company has compiled a library of approximately 550 individual human and rodent immunoassays for use in its MAP testing services and is continuously adding new assays to this library. The company has assembled the most clinically relevant human immunoassays from this library into its DiscoveryMAP assay panel, which the company employs with pharmaceutical collaborators in human clinical trials. The company has also developed RodentMAP, a proprietary panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assist researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The company has licensed rights to the Luminex platform used in its MAP testing services. TruCulture: TruCulture is a self-contained whole blood culture that could be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities. The TruCulture system might allow pharmaceutical and biotechnology companies to identify drug toxicity prior to human trials, potentially enabling a decision as to whether to continue a drug’s development earlier in the development process. Multiplexed Immunoassay Kits: Majority of the company’s pharmaceutical and biotechnology customers need bioassay kits for complimentary in-house testing. Therefore, it has developed multiplexed immunoassay kits that enable the company’s customers to leverage its technology services with their in-house capabilities. Acquisitions In February 2014, the company completed the acquisition of privately-held Crescendo Bioscience, Inc. (Crescendo). The business of Crescendo, including its VectraDA blood test for RA disease management, is operated as a wholly owned subsidiary. License Agreements The company has a license agreement with the University of Utah Research Foundation (the ‘University’), for the rights to utilize certain intellectual property rights of the University, including issued patents that relate to the BRCA1 gene, on a worldwide basis. The company has separate license agreements with the University; Endorecherche, Inc.; The Hospital for Sick Children; and The Trustees of the University of Pennsylvania (collectively referred to as the ‘BRCA2 Licensors’) for rights to utilize certain intellectual property rights of the respective BRCA2 Licensors, including issued patents that relate to the BRCA2 gene, on a worldwide basis. The company has license agreements with Genzyme Corporation and with Dana-Farber Cancer Institute, Inc.; Oregon Health Sciences University; University of Vermont; State Agricultural College; and Yale University (collectively the ‘COLARIS Licensors’) for the non-exclusive rights to utilize certain intellectual property rights of the COLARIS Licensors, including issued patents that relate to the MLH1, MSH2 and PMS2 genes, on a worldwide basis. Business Strategy The company’s business strategy for future growth is focused on three key initiatives. First, it is working to improve and expand its existing products and markets. Second, it is developing its business internationally with an international direct sales force. Finally, the company is launching and inten


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MYGN:US $35.75 USD +0.29

MYGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advanced Drainage Systems Inc $28.36 USD +0.28
Alliance HealthCare Services Inc $13.75 USD +0.15
Genomic Health Inc $27.28 USD +0.55
RadNet Inc $6.12 USD -0.09
View Industry Companies

Industry Analysis


Industry Average

Valuation MYGN Industry Range
Price/Earnings 31.9x
Price/Sales 3.3x
Price/Book 3.6x
Price/Cash Flow 29.4x
TEV/Sales 3.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MYRIAD GENETICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at